Day: April 8, 2025
AB Vilkyškių pieninė (hereinafter referred to as the Company), company code 277160980, by the initiative and decision of the Board, convenes the Ordinary General Meeting of Shareholders on 29 April 2025, at 9:00 AM at the Company’s registered seat address at P. Lukošaičio st. 14, Vilkyškiai, LT-99254 Pagėgiai municipality.
Shareholder registration will begin at 8:00 AM and will end at 8:50 AM.
AGENDA OF THE ORDINARY GENERAL MEETING OF SHAREHOLDERS:Regarding the independent auditor’s report on the Company’s 2024 separated and consolidated financial statements and the limited assurance auditor’s report on the consolidated Sustainability Statement.
Regarding the Supervisory Board’s feedback and proposals.
Regarding agreement of the Company’s 2024 consolidated and separated annual management report.
Regarding approval...
Nexus Industrial REIT Announces the Sale of Legacy Retail and Office Buildings and Leasing Update
Written by Customer Service on . Posted in Public Companies.
OAKVILLE, Ontario, April 08, 2025 (GLOBE NEWSWIRE) — Nexus Industrial REIT (“Nexus” or the “REIT”) (TSX: NXR.UN) is pleased to announce the sale of its 50% ownership interest in 15 retail buildings located in Quebec for $47 million and one office building also located in Quebec for $4 million, representing cap rates on in-place rents of 6.8% and 9.5% respectively (together, the “Properties”). The REIT intends to use the net proceeds from the dispositions to repay existing indebtedness on its credit facility and to fund development projects.
“These sales mark the substantial completion of our transition to a pure-play, Canada-focused industrial REIT” said Kelly Hanczyk, CEO of Nexus Industrial REIT. “Over the past five years we have successfully re-focused and grown Nexus to be a scale pure-play industrial REIT, with...
Banco Comercial Português, S.A. informs on the approval of a Share Buyback Programme
Written by Customer Service on . Posted in Public Companies.
Banco Comercial Português, S.A. informs on the approval of a Share Buyback ProgrammeAttachment2025 04 08 SBB EN
RCI Banque: ‘’Pillar III Report as at December 31th 2024’’
Written by Customer Service on . Posted in Public Companies.
April 8th, 2024
RCI Banque: ‘’Pillar III Report as at December 31th 2024’’
The RCI BANQUE: Pillar Report as at December 31th 2024 is now available on the Mobilize Financial Services website www.mobilize-fs.comAttachmentsPILLAR 3 DISCLOSURE 2024-12-31-VDEV 04 2025Press Release – Pillar III Report 2024
RCI Banque: ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available”
Written by Customer Service on . Posted in Public Companies.
April 8th, 2025
RCI Banque: ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available.”
The RCI Banque group ‘’Consolidated Financial Statements as at December 31th 2024’’ is now available on the Mobilize Financial Services website www.mobilize-fs.comAttachmentsRCI_Banque_-_RCC_2024 ENPress Release – Consolidated Financial Statements as at 31 december 2024
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
The Company provided an update on patient demand metrics that was in line with guidance from its full-year results announcement on March 3, 2025. It also addressed questions related to the recent developments in United States tariff policy and the potential impact on the biopharmaceutical sector, including Avadel.
Specifically:In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 2024. These improvements include patient enrollments, patient starts, persistency...
Costamare Inc. Announces Details for the Upcoming Costamare Bulkers Holdings Limited Virtual Analyst and Investor Day
Written by Customer Service on . Posted in Public Companies.
MONACO, April 08, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) announces Conference Call Details for the virtual Analyst and Investor Day that the incoming management team of Costamare Bulkers Holdings Limited (“Costamare Bulkers”) will host on Wednesday April 9, 2025, at 9:00 a.m. Eastern Daylight Time. Costamare Bulkers is the new company that will hold Costamare Inc.’s owned dry bulk vessels and the CBI operating platform upon completion of Costamare Inc.’s previously announced spin-off of its dry bulk business.
Conference Call Details:
On Wednesday, April 9, 2025 at 9:00 a.m. ET, the incoming management team of Costamare Bulkers will hold a conference call to discuss Costamare Bulkers’ core business and operations, investment highlights, and strategic outlook, followed by a Q&A session.
Participants...
Eloro Resources Announces Closing of Brokered Private Placement for Gross Proceeds of C$5.3 Million
Written by Customer Service on . Posted in Public Companies.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
TORONTO, April 08, 2025 (GLOBE NEWSWIRE) — Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) (“Eloro” or the “Company”) is pleased to announce the closing of its previously announced best efforts private placement (the “Offering“) for aggregate gross proceeds of C$5,275,101, which includes the partial exercise of the agents’ option for gross proceeds of C$275,101. Under the Offering, the Company sold an aggregate of 5,552,738 units of the Company (the “Units”) at a price of C$0.95 per Unit (the “Offering Price”).
Each Unit consists of one common share of the Company (each, a “Unit Share”) and one half of one common share...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Written by Customer Service on . Posted in Public Companies.
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis
Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS
Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression...
Societe Generale announces results of the offer to purchase certain of its debt securities
Written by Customer Service on . Posted in Public Companies.
SOCIETE GENERALE ANNOUNCES RESULTS OF THE OFFER TO PURCHASE CERTAIN OF ITS DEBT SECURITIES
Press release
Paris, April 8, 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE OR TO WHOM IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.
Further to the announcement on April 1, 2025 of the launch of an offer to purchase for cash (the “Offer”) any and all of its outstanding Undated Deeply Subordinated Resettable Interest Rate Notes referred to below (the “Notes”), Societe Generale today announces the results of the Offer.
The expiration time for the Offer was 5:00 p.m. (New York City time) on April 7, 2025.
According to information provided by the Tender and Information Agent for the Offer, $710,342,000 aggregate principal amount of the Notes were validly...